Tibet AIM Pharm. Inc. (SZSE: 002826)
Health Care · Pharmaceuticals · CN
CN¥17.34
-1.87% today · -21.9% 1Y
Tibet AIM Pharm. Inc. (SZSE: 002826) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $490.28M and employs 405 people.
Over the last twelve months the share price has lost 21.9%, trading between 14.65 and 23.19.
Tweenvest scores Tibet AIM Pharm. Inc. across four factors: quality 78/100, value 44/100, growth 44/100, dividend 69/100. Its strongest factor is quality.
002826 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $490.28M
- Revenue (TTM)
- $97.18M
- P/E
- 33.93
- EPS
- 0.51
- Dividend yield
- 0.86%
- Beta (5Y)
- 0.35
- 52-week high
- CN¥23.19
- 52-week low
- CN¥14.65
- Avg volume (3M)
- —
- Shares outstanding
- 190.07M
- Employees
- 405
- Next earnings
- —
About Tibet AIM Pharm. Inc.
Headquartered in Beijing, China, Tibet AIM Pharm. Inc. was established in 2003 to conduct research and develop medical products across China. The company's diverse pharmaceutical portfolio targets a range of health conditions. Among its offerings are Miglitol tablets for managing diabetes and Gualoupi injection, prescribed for coronary disease. It also provides Oxytocin injection for gynecological and obstetric applications, alongside Carbetocin injections. A significant product is NalMefene injection, which is employed for treating various acute toxicities, such as those from alcohol, organic phosphorus, carbon monoxide, sedative-hypnotics, and opioid substances. Furthermore, it is indicated for serious infections, shock, syncope, and certain neurological issues. Completing its product line are Hongjin Xiaojie tablets and Aceclofenac Enteric-Coated tablets, with therapeutic areas also extending to anti-infective, anti-allergic, and digestive system treatments.
- ISIN
- CNE100002C39
- Founded
- 2003
- Listed since
- Dec 12, 2016
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.